Benitec Biopharma
BNTC
12 hedge funds and large institutions have $3.84M invested in Benitec Biopharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 8 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
47.4% more ownership
Funds ownership: 2.32% → 49.72% (+47%)
29% less funds holding
Funds holding: 17 → 12 (-5)
31% less capital invested
Capital invested by funds: $5.57M → $3.84M (-$1.73M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$641K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$588K |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$494K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$216K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.8K |
| 2 |
VF
Virtu Financial
New York
|
-$13K |
| 3 |
Morgan Stanley
New York
|
-$9.21K |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.11K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$3.14K |
BNTC Hedge Fund Activity: Q3 2023 in Review
12 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2023, worth a combined $3.84M — down 31% from $5.57M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BNTC and 3 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 7 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $641K. The largest seller was Vanguard Group, exiting entirely with an estimated $17.8K sold.
- 12 institutional investors held Benitec Biopharma (BNTC) as of Q3 2023, down from 17 in Q2 2023.
- Funds reported $3.84M of Benitec Biopharma stock for Q3 2023, down 31% quarter-over-quarter.
- 3 funds opened new Benitec Biopharma positions in Q3 2023 and 8 closed out, a net change of -5 holders.
- The largest Benitec Biopharma buyer in Q3 2023 was Janus Henderson Group, an estimated $641K added.
- The largest Benitec Biopharma seller in Q3 2023 was Vanguard Group, an estimated $17.8K sold.
Based on aggregated 13F filings for Q3 2023.